Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 20;26(9):684-691.
doi: 10.3779/j.issn.1009-3419.2023.102.33.

[Drug Resistance Mechanism and Therapeutic Strategy of Targeted Therapy of Non-small Cell Lung Cancer with MET Alterations]

[Article in Chinese]
Shuzhan Li  1 , Xinwei Zhang  1
Affiliations

[Drug Resistance Mechanism and Therapeutic Strategy of Targeted Therapy of Non-small Cell Lung Cancer with MET Alterations]

[Article in Chinese]
Shuzhan Li et al. Zhongguo Fei Ai Za Zhi. .

Abstract
in English, Chinese

Mesenchymal to epithelial transition factor (MET) gene alterations involve in the proliferation, invasion, and metastasis of non-small cell lung cancer. MET-tyrosine kinase inhibitors (TKIs) have been approved to treat non-small cell lung cancer with MET alterations, and resistance to these TKIs is inevitable. Molecular mechanisms of resistance to MET-TKIs are completely unclear. The review focused on potential mechanisms of MET-TKIs resistance and therapeutics strategies to delay and prevent resistance. .

【中文题目：MET基因改变的非小细胞肺癌靶向治疗 耐药机制及治疗策略】 【中文摘要：间质表皮转化因子（mesenchymal to epithelial transition factor, MET）基因改变参与了非小细胞肺癌的增殖、侵袭和转移。MET-酪氨酸激酶抑制剂（tyrosine kinase inhibitors, TKIs）已获批用于MET基因改变的非小细胞肺癌，而这些药物的耐药不可避免。MET-TKIs的分子耐药机制错综复杂，尚不完全清楚。本文主要对这些MET-TKIs的潜在耐药机制进行综述，以期为MET基因改变的患者提供合理的治疗思路。 】 【中文关键词：肺肿瘤；间质表皮转化因子；靶向治疗；耐药；治疗策略】.

Keywords: Drug resistance; Lung neoplasms; Mesenchymal to epithelial transition factor; Targeted therapy; Treatment strategy.

PubMed Disclaimer

Figures

Fig 1
图1. MET-TKIs的获得性耐药分为MET依赖型耐药机制与非MET依赖型耐药机制。MET依赖型耐药包括MET分子的二次点突变与MET扩增。非MET依赖型耐药包括了MET下游通路与旁路信号通路的激活。谷美替尼因上市时间短无相关报道。
Fig 2
图2. MET-TKIs耐药后治疗决策的流程图
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Siegel RL, Miller KD, Fuchs HE, et al. . Cancer statistics, 2022. CA Cancer J Clin, 2022, 72(1): 7-33. doi: 10.3322/caac.21708 - DOI - PubMed
    1. Van Der Steen N, Giovannetti E, Pauwels P, et al. . cMET exon 14 skipping: from the structure to the clinic. J Thorac Oncol, 2016, 11(9): 1423-1432. doi: 10.1016/j.jtho.2016.05.005 - DOI - PubMed
    1. Sierra JR, Tsao MS. . c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol, 2011, 3(1 Suppl): S21-S35. doi: 10.1177/1758834011422557 - DOI - PMC - PubMed
    1. Owusu BY, Galemmo R, Janetka J, et al. . Hepatocyte growth factor, a key tumor-promoting factor in the tumor microenvironment. Cancers (Basel), 2017, 9(4): 35. doi: 10.3390/cancers9040035 - DOI - PMC - PubMed
    1. Scagliotti GV, Novello S, von Pawel J. . The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev, 2013, 39(7): 793-801. doi: 10.1016/j.ctrv.2013.02.001 - DOI - PubMed

Publication types

MeSH terms